United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ares Capital

Enterprise Products Partners

Energy Transfer LP Unit

Verizon

These stocks offer dividend yields of nearly 6.2% to almost 9.4%. Several of them boast impressive track records of dividend growth.

My Top-5 Ultrahigh-Yield Dividend Stocks to Buy in April

AbbVie

Gilead Sciences

AbbVie offers one of the most attractive dividends around. Gilead Sciences provides stability and consistency to income investors.

3 No-Brainer Dividend Stocks to Buy in April

Taiwan Semiconductor Manufacturing

In the dynamic world of investing, uncovering value amidst market fluctuations is a quest pursued by many. Reddit's r/ValueInvesting community provides a unique platform where investors converge to share insights and identify potential opportunities.

Redditors Discuss What The Top 3 Value Stock Picks Are Right Now - Pfizer (NYSE:PFE), Taiwan Semiconductor (NYSE:TSM)

Bristol-Myers

Moderna

With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one's buck. For new investors seeking reasonable valuations and overlooked long-term growth drivers, the biotech scene is worth considering.

The 3 Most Undervalued Biotech Stocks to Buy in April 2024

Disney

Intel

PayPal

Tesla

Amidst turbulent economic conditions, investors are actively searching for steady prospects for expansion and recovery. Here, seven companies, though they are in different industries, have one thing in common: they are resilient and strategically minded.

The Comeback Kids: 7 Stocks Ready to Rise from the Ashes

Pfizer stock remains under pressure despite becoming one of the biggest names of the pandemic. Is PFE stock a sell?

Is Pfizer Stock A Sell As Shares Hit A Fresh Low Amid The Search For Its Next Big Break?

Johnson & Johnson

Merck

Pfizer's patent expirations are great for humanity but terrible for investors. It's a common story across the drug industry.

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.

Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs.

After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?

Alliance Resource Partners

Innovative Industrial Properties

Dividend stocks have more than doubled up the average annual return of non-payers over the last 50 years. Though higher-yield stocks come with added risks, a number of amazing income producers can be uncovered with proper vetting.

3 Magnificent Ultra-High-Yield Dividend Stocks That Are Screamings Buys in April

Amazon

ASML Hld

Microsoft

Visa

Walmart

Exxon Mobil

Blue Chip stocks are among the most dependable investments available. For that reason many investors believe them to be an unbeatable investment overall.

Unbeatable Blue Chips: 7 Must-Own Stocks for Every Portfolio

Home Depot

McDonald's

Procter & Gamble

Target

It's an interesting time in the market, which may bode well for conservative ideas found among blue-chip stocks. Underlying this category are some of the strongest, most established businesses and brands in the world, making them ideal for addressing various anxieties.

Blue-Chip Bulldozers: 7 Stock Giants to Plow Through a Wall of Worries

Vaccine makers Pfizer and Moderna lost much of their steam as the pandemic started receding. However, both businesses are making significant strides and their shares should bounce back.

2 Stocks Down 30% and 27% to Buy and Hold

SPDR S&P 500 ETF Trust

Ford Motor Company

Altria

The first quarter of the year was a success for investors. The overall market NYSE: SPY surged nearly 10%, fueled by robust economic indicators, optimism, and hype surrounding AI.

4 Dividend Aristocrats Trading at a Discount

Pfizer and Moderna, both coronavirus vaccine stars, now face declining demand -- and, as a result, declining revenue. But these top companies are expanding their growth potential with new candidates targeting various treatment areas.

Better Recovery Story Buy: Pfizer vs Moderna

Viking Therapeutics

Viking Therapeutics may be on the verge of a breakthrough obesity care treatment. Right now, obesity care and diabetes are dominated by Novo Nordisk and Eli Lilly.

Prediction: Pfizer Won't Acquire Viking Therapeutics. Here's Why.

BHP Billiton

Philip Morris

AT&T

Toronto-Dominion Bank

Sponsored: Find a Qualified Financial Advisor Finding a qualified financial advisor doesn't have to be hard.

5 Very Large Cap Blue Chip Stocks With 5% and Higher Dividends

Horace Mann Educators

International Bancshares Corp.

Northrim BanCorp

Trinity Industries

Walgreens

Check out the guide to the best dividend stocks that can help you achieve financial freedom. The first star in this investing galaxy, with a 5% dividend yield, is glowing brightly.

7 Dividend Stocks to Secure Your Financial Freedom by 2026

Paychex

TROY, Mich. , March 28, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Paychex Inc. (NYSE: PAYX) as its "Stock to Study" and Pfizer Inc. (NYSE: PFE) as its "Undervalued Stock" in the June/July 2024 issue for investors' informational and educational use.

BetterInvesting™ Magazine Update on Paychex Inc. and Pfizer Inc.

News for Pfizer Stock (PFE)